Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 14,715 shares of the medical equipment provider’s stock after selling 3,110 shares during the period. Sanctuary Advisors LLC’s holdings in Zimmer Biomet were worth $1,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ZBH. Roman Butler Fullerton & Co. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $473,000. Geode Capital Management LLC lifted its stake in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares during the last quarter. M&T Bank Corp boosted its holdings in shares of Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after acquiring an additional 8,709 shares during the period. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $654,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.1 %

Shares of Zimmer Biomet stock opened at $106.00 on Tuesday. The company has a 50-day moving average of $105.85 and a two-hundred day moving average of $107.44. The stock has a market cap of $21.10 billion, a PE ratio of 23.82, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 earnings per share. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ZBH shares. Wells Fargo & Company raised their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.